Stock A115180 QURIENT CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Qurient Co., Ltd.

Equities

A115180

KR7115180002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
3,690 KRW -0.14% Intraday chart for Qurient Co., Ltd. -0.54% -20.99%
21/05 Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC CI
17/05 Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 2,89,037 3,71,356 3,43,320 1,20,105 90,356
Enterprise Value (EV) 1 2,71,032 3,13,780 2,92,285 87,814 47,869
P/E ratio -13 x -16.6 x -15.4 x -5.02 x -3.91 x
Yield - - - - -
Capitalization / Revenue - - 7,02,67,270 x 1,41,82,506 x 1,00,04,182 x
EV / Revenue - - 5,98,21,903 x 1,03,69,450 x 53,00,023 x
EV / EBITDA -11.9 x -15.3 x -12.4 x -3.28 x -2.14 x
EV / FCF - -2,57,57,721 x -1,80,44,033 x -56,98,936 x -34,81,032 x
FCF Yield - -0% -0% -0% -0%
Price to Book 17.6 x 6.72 x 6.87 x 4.24 x 2.87 x
Nbr of stocks (in thousands) 12,320 14,178 14,730 14,730 19,348
Reference price 2 23,462 26,192 23,308 8,154 4,670
Announcement Date 17/03/21 17/03/21 17/03/22 17/03/23 20/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales - - 4,886 8,469 9,032
EBITDA 1 -22,725 -20,484 -23,578 -26,758 -22,394
EBIT 1 -23,170 -21,025 -24,243 -27,475 -23,213
Operating Margin - - -496.18% -324.43% -257.02%
Earnings before Tax (EBT) 1 -22,698 -20,773 -23,884 -27,118 -22,249
Net income 1 -22,698 -20,498 -22,848 -25,457 -21,117
Net margin - - -467.63% -300.61% -233.8%
EPS 2 -1,800 -1,575 -1,518 -1,623 -1,193
Free Cash Flow - -12,182 -16,198 -15,409 -13,751
FCF margin - - -331.53% -181.95% -152.25%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 17/03/21 17/03/21 17/03/22 17/03/23 20/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 - - - - -
Net Cash position 1 18,004 57,576 51,035 32,291 42,487
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -12,182 -16,198 -15,409 -13,751
ROE (net income / shareholders' equity) - -55.9% -42.7% -60.8% -52.3%
ROA (Net income/ Total Assets) - -32.3% -25.6% -35.8% -31.9%
Assets 1 - 63,429 89,294 71,185 66,164
Book Value Per Share 2 1,330 3,895 3,395 1,922 1,627
Cash Flow per Share 2 295.0 327.0 1,254 1,307 1,241
Capex 1 12.5 10.7 147 12.8 -
Capex / Sales - - 3% 0.15% -
Announcement Date 17/03/21 17/03/21 17/03/22 17/03/23 20/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
QURIENT CO., LTD. Stock Qurient Co., Ltd.
-20.99% 87.64M
MCKESSON CORPORATION Stock McKesson Corporation
+29.50% 78.4B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+0.30% 25.12B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+14.70% 8.62B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+0.73% 8.55B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-28.87% 6.91B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+16.06% 5.34B
GALENICA AG Stock Galenica AG
+1.58% 4.17B
EBOS GROUP LIMITED Stock EBOS Group Limited
-8.90% 3.82B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
-7.62% 3.37B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. A115180 Stock
  4. Financials Qurient Co., Ltd.